Small Cap Profits.com Featured Article: (Nasdaq CM: NLTX)

Industry: Biotechnology

Nile Therapeutics, Inc. (Nasdaq CM: NLTX)

Received Notification: June 18, 2010

Compliance Required by December 15, 2010

The company is in violation of the $1.00 minimum requirement. The company recently raised $4 million in capital for their ongoing Phase II trial of CD-NP in acute heart failure patients, which resulted in the dilution. The public offering increased the total outstanding shares by approximately 20%. NLTX was falling since last September, but really crashed since the public offering in early April.  More information on NLTX can be found on the Company website at www.nilethera.com

___________________________________________________________________________